BioCentury | Jan 13, 2020
Politics, Policy & Law

Supreme Court declines to clean up its IP mess

Over the last decade the U.S. Supreme Court has issued a series of decisions on the patentability of diagnostics that have befuddled lower courts, stifled investment, and led former U.S. Patent and Trademark Director David...
BC Extra | Jan 13, 2020
Clinical News

Academic sponsors lag industry in reporting clinical trial results

An analysis of compliance with U.S. clinical trial reporting laws and regulations found widespread failures among academic institutions and a higher reporting rate among biopharma companies. Science investigated compliance with a law that required sponsors...
BC Extra | Jan 9, 2020
Financial News

Jan. 8 Financial Quick Takes: Intra-Cellular raises $295M; plus venture rounds for nference, Eyevensys, Transcenta, Airway, Progentec

Intra-Cellular raises $295M  In an offering priced late Tuesday, Intra-Cellular Therapies Inc. (NASDAQ:ITCI) raised $295 million through the sale of 10 million shares at $29.50. The price is a 4% discount to Intra-Cellular’s close at...
BC Extra | Jan 8, 2020
Financial News

Novome raises $33M series A, shoots for the gut with engineered microbes

Novome’s engineered microbe platform attracted DCVC Bio to lead its $33 million series A because of the potential it offers for a non-invasive mechanism to deliver biologics to the gut, a long-standing industry goal. The...
BioCentury | Dec 20, 2019
Emerging Company Profile

Centaurus: inhibiting ceramide synthesis for cardiometabolic disease

Centaurus is aiming for first-in-class small molecules that block the lipotoxicity driving cardiometabolic diseases. Stress stimuli such as inflammation increase production of the structural lipid ceramide, which induces apoptosis, necroptosis and cellular metabolism defects. Centaurus...
BC Innovations | Dec 10, 2019
Emerging Company Profile

Zentalis debuts with trio of clinical oncology programs, $85M series C

Zentalis emerged from stealth Monday with an untranched and oversubscribed $85 million series C and three internally discovered clinical cancer candidates, with plans to begin pivotal testing by 2021. The C round syndicate includes Matrix...
BC Innovations | Nov 22, 2019
Distillery Therapeutics

Dopamine receptor agonism for pulmonary fibrosis, liver fibrosis

DISEASE CATEGORY: Pulmonary; hepatic INDICATION: Pulmonary fibrosis; liver fibrosis Agonism of the dopamine receptor DRD1 could treat pulmonary and liver fibrosis. In cultures of lung fibroblasts derived from patients with idiopathic pulmonary fibrosis (IPF), a...
BC Extra | Nov 7, 2019
Financial News

Nov. 6 Financial Quick Takes: NEA backs Shape's series A; plus Royalty-Eisai-Epizyme, Sinomed, Genecast and Cadence

Shape raises $35.5M A round  RNA editing company Shape Therapeutics Inc. raised $35.5 million in a series A round led by New Enterprise Associates, with participation from CureDuchenne Ventures. The company uses guide RNAs to...
BC Extra | Oct 17, 2019
Preclinical News

Oct. 17 Preclinical Quick Takes: Miromatrix, Mayo extend vascular function in liver graft scaffold; plus James Allison-MD Anderson, Northwestern and Eleusis

Extending vascular function in bioengineered liver graft scaffold  Miromatrix Inc. and Mayo Clinic researchers developed a way to vascularize bioengineered liver scaffolds that could maintain blood flow for more than a few days. Described in...
BC Innovations | Aug 15, 2019
Distillery Techniques

Mayo Clinic liquid biopsy for breast cancer residual disease

TECHNIQUES CATEGORY: Assays and Screens TECHNOLOGY: Diagnostic Assays A Mayo Clinic team reported that a personalized multiplex sequencing approach called TARDIS (targeted digital sequencing) could accurately distinguish pathological complete response from residual disease following cancer...
Items per page:
1 - 10 of 450
BioCentury | Jan 13, 2020
Politics, Policy & Law

Supreme Court declines to clean up its IP mess

Over the last decade the U.S. Supreme Court has issued a series of decisions on the patentability of diagnostics that have befuddled lower courts, stifled investment, and led former U.S. Patent and Trademark Director David...
BC Extra | Jan 13, 2020
Clinical News

Academic sponsors lag industry in reporting clinical trial results

An analysis of compliance with U.S. clinical trial reporting laws and regulations found widespread failures among academic institutions and a higher reporting rate among biopharma companies. Science investigated compliance with a law that required sponsors...
BC Extra | Jan 9, 2020
Financial News

Jan. 8 Financial Quick Takes: Intra-Cellular raises $295M; plus venture rounds for nference, Eyevensys, Transcenta, Airway, Progentec

Intra-Cellular raises $295M  In an offering priced late Tuesday, Intra-Cellular Therapies Inc. (NASDAQ:ITCI) raised $295 million through the sale of 10 million shares at $29.50. The price is a 4% discount to Intra-Cellular’s close at...
BC Extra | Jan 8, 2020
Financial News

Novome raises $33M series A, shoots for the gut with engineered microbes

Novome’s engineered microbe platform attracted DCVC Bio to lead its $33 million series A because of the potential it offers for a non-invasive mechanism to deliver biologics to the gut, a long-standing industry goal. The...
BioCentury | Dec 20, 2019
Emerging Company Profile

Centaurus: inhibiting ceramide synthesis for cardiometabolic disease

Centaurus is aiming for first-in-class small molecules that block the lipotoxicity driving cardiometabolic diseases. Stress stimuli such as inflammation increase production of the structural lipid ceramide, which induces apoptosis, necroptosis and cellular metabolism defects. Centaurus...
BC Innovations | Dec 10, 2019
Emerging Company Profile

Zentalis debuts with trio of clinical oncology programs, $85M series C

Zentalis emerged from stealth Monday with an untranched and oversubscribed $85 million series C and three internally discovered clinical cancer candidates, with plans to begin pivotal testing by 2021. The C round syndicate includes Matrix...
BC Innovations | Nov 22, 2019
Distillery Therapeutics

Dopamine receptor agonism for pulmonary fibrosis, liver fibrosis

DISEASE CATEGORY: Pulmonary; hepatic INDICATION: Pulmonary fibrosis; liver fibrosis Agonism of the dopamine receptor DRD1 could treat pulmonary and liver fibrosis. In cultures of lung fibroblasts derived from patients with idiopathic pulmonary fibrosis (IPF), a...
BC Extra | Nov 7, 2019
Financial News

Nov. 6 Financial Quick Takes: NEA backs Shape's series A; plus Royalty-Eisai-Epizyme, Sinomed, Genecast and Cadence

Shape raises $35.5M A round  RNA editing company Shape Therapeutics Inc. raised $35.5 million in a series A round led by New Enterprise Associates, with participation from CureDuchenne Ventures. The company uses guide RNAs to...
BC Extra | Oct 17, 2019
Preclinical News

Oct. 17 Preclinical Quick Takes: Miromatrix, Mayo extend vascular function in liver graft scaffold; plus James Allison-MD Anderson, Northwestern and Eleusis

Extending vascular function in bioengineered liver graft scaffold  Miromatrix Inc. and Mayo Clinic researchers developed a way to vascularize bioengineered liver scaffolds that could maintain blood flow for more than a few days. Described in...
BC Innovations | Aug 15, 2019
Distillery Techniques

Mayo Clinic liquid biopsy for breast cancer residual disease

TECHNIQUES CATEGORY: Assays and Screens TECHNOLOGY: Diagnostic Assays A Mayo Clinic team reported that a personalized multiplex sequencing approach called TARDIS (targeted digital sequencing) could accurately distinguish pathological complete response from residual disease following cancer...
Items per page:
1 - 10 of 450